Immunicum AB (publ) and Academic Collaborators Publish Preclinical Ilixadencel Mode of Action Data in Journal Oncoimmunology
(Thomson Reuters ONE) -
Press Release
10 November 2017
Immunicum AB (publ) and Academic Collaborators Publish Preclinical Ilixadencel
Mode of Action Data in Journal Oncoimmunology
Immunicum AB (publ; First North Premier: IMMU.ST), a biopharmaceutical company
advancing a novel, immune-priming cancer treatment against a variety of solid
tumors, today announced two online publications of preclinical studies
investigating the mode of action of lead program ilixadencel in the prestigious
scientific journal Oncoimmunology. The studies show the multiple ways in which
ilixadencel, or corresponding allogeneic proinflammatory mouse dendritic cells,
create an immune-priming environment. Excerpts of the in vitro study were
recently presented in a poster at the Society for Immunotherapy of Cancer (SITC)
32(nd) Annual Meeting http://bit.ly/2zq2eBZ.
The publications in Oncoimmunology conducted in collaboration with Professor
Magnus Essand's research group at Uppsala University, showed the following:
* Ilixadencel addresses several key complementary immunological mechanisms to
increase the capacity of the immune system to more efficiently recognize and
destroy tumor cells.
* Additional data from the cell culture studies demonstrated that ilixadencel
boosts the ability of bystander dendritic cells (corresponding to the
patients dendritic cells) to capture, process and present released tumor
antigens leading to a subsequent activation of tumor-specific cytotoxic T-
cells, which are important in the effective long-term destruction of tumor
cells.
* In the mouse tumor models, researchers were able to show that a local
subcutaneous injection of allogeneic proinflammatory mouse dendritic cells
(alloDCs) induced migration of activated host dendritic cells to the
draining lymph node. Intratumoral injection of alloDCs furthermore altered
the immunosuppressive tumor micro-environment in these mice resulting in a
pro-inflammatory milieu that led to the recruitment of NK cells and CD8+ T
cells to the treated tumor.
"The new data that now has been published, show the ability of ilixadencel, and
corresponding allogeneic proinflammatory mouse dendritic cells, to stimulate
several very important mechanisms to induce tumor-specific immune responses,"
said Alex Karlsson-Parra, Chief Scientific Officer of Immunicum. "The results
further underscore the impact our technology could have in modern cancer
treatment regimens and is in line with the promising signs of efficacy we have
seen in the clinical trials with ilixadencel."
As part of the expanded data on ilixadencel's mode of action, the two studies
also investigated the novel approach Immunicum is evaluating for potential
subcutaneous injection in certain types of tumor diseases. This approach is
based on the same principles as for ilxadencel with the addition of Immunicum's
proprietary adenovirus vector Ad5PTDf35 used for transfection of ilixadencel
with genes coding for tumor-specific antigens. Using this model, the researchers
could replicate the immune system priming effect seen with non-transfected
ilixadencel in vitro and mouse alloDC in vivo. Additional studies are needed to
investigate the benefits and the safety profile to define the capabilities of
this novel approach and how it could complement Immunicum's pipeline.
Immunicum's lead program ilixadencel has been tested in over 85 patients to
date. Completed Phase 1/2 studies in renal cell carcinoma and hepatocellular
carcinoma have shown a favourble safety profile and initial signs of efficacy.
There is clinical development ongoing in a Phase 2 trial in renal cell
carcinoma (MERECA) as well as a Phase 1/2 study in gastrointestinal stromal
tumors (GIST).
The full publications titled "Pro-inflammatory allogeneic DC's promote
activation of bystander immune cells and thereby license antigen specific T-cell
responses" and "Cancer vaccine based on a combination of an infection-enhanced
adenoviral vector and pro-inflammatory allogeneic DCs lead to sustained antigen-
specific immune responses in three melanoma models" can be accessed through the
current online version of Oncoimmunology and the following link.
http://bit.ly/2j9pePF
About ilixadencel
Ilixadencel cell therapy product (formerly known as INTUVAX®) is an off-the-
shelf cancer immune primer, developed for the treatment of solid tumors. Its
active ingredient is activated allogeneic dendritic cells, derived from healthy
blood donors. Intratumoral injection of these cells is expected to lead to an
inflammatory response which in turn leads to tumor-specific activation of the
patient's cytotoxic T-lymphocytes.
For more information, please contact:
Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info(at)immunicum.com
Investor Relations Sweden
Helena Stångberg
Hallvarsson & Halvarsson
Telephone: + 46 709 71 12 53
E-mail: ir(at)immunicum.com
Investor and Media Relations EU/US
MacDougall Biomedical Communications
Gretchen Schweitzer or Stephanie May
Telephone: +49 89 2424 3494 or +49 175 5711562
E-mail: ir(at)immunicum.com
The Company's Certified Adviser is Redeye AB
Telephone: +46 (0)8 545 013 30
www.redeye.se
About Immunicum AB (publ)
Immunicum is establishing a unique immuno-oncology approach through the
development of allogeneic, off-the-shelf cell-based therapies. Our goal is to
improve survival outcomes and quality of life by priming the patient's own
immune system to fight cancer. The company's lead product ilixadencel,
consisting of pro-inflammatory allogeneic dendritic cells, has the potential
to become a backbone component of modern cancer combination treatments in a
variety of solid tumor indications. Founded and based in Sweden, Immunicum is
publicly traded on the Nasdaq First North Premier. www.immunicum.com
-------------------------------------------------------------------------------
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Immunicum AB via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 10.11.2017 - 12:00 Uhr
Sprache: Deutsch
News-ID 567663
Anzahl Zeichen: 7211
contact information:
Town:
Gothenburg
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 216 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Immunicum AB (publ) and Academic Collaborators Publish Preclinical Ilixadencel Mode of Action Data in Journal Oncoimmunology"
steht unter der journalistisch-redaktionellen Verantwortung von
Immunicum AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
